生物医药系列产品
数据
资源
版本对比
免费注册
预约演示
免费注册
Valbiotis
Announces That It Has Submitted to the Competent Authorities the Three Clinical Protocols for TOTUM•854 Indicated in the Reduction of Blood Pressure and Presents Its Comprehensive Clinical Development Plan
2021-12-01
·
BioSpace
合作
Dec. 1, 2021 06:35 UTC The INSIGHT international, multicenter, randomized, placebo-controlled pivotal Phase II/III clinical study will be conducted with a 3.7 g/day dose of TOTUM•854 on 400 volunteers; The INSIGHT 2 international, multicenter, randomized, placebo-controlled Phase II/III clinical study will be conducted with a 2.6 g/day dose of TOTUM•854 on 400 volunteers; The clinical study of the bioavailability and mode of action of TOTUM•854, to characterize its metabolites and identify their effects on human cell lines, will be conducted in France on 10 volunteers. LA ROCHELLE, France--(BUSINESS WIRE)-- Regulatory News:
Valbiotis
(FR0013254851 – ALVAL, PEA/SME eligible) (Paris:AVAL), a Research and Development company committed to scientific innovation for preventing and combating
metabolic and cardiovascular diseases
, announces that it has submitted the three clinical protocols for TOTUM•854, indicated in the reduction of blood pressure, to the competent authorities and presents its comprehensive clinical development plan, as announced at the annual meeting of the European Society of
Hypertension
and of the International Society of
Hypertension
in April 2021 (Press release dated April 12, 2021). TOTUM•854 is the second plant-based active substance from the
Valbiotis
product portfolio to enter Phase II/III clinical trials and will address an unmet medical demand for non-drug prevention of
arterial hypertension
. The TOTUM•854 clinical development program includes three clinical studies, whose results will be required in Europe and the United States for health claim applications in the reduction of blood pressure, which is a risk factor for
cardiovascular disease
. The clinical protocols for the three studies have been filed with the competent authorities. The INSIGHT international, multicenter, randomized, placebo-controlled Phase II/III clinical study will be conducted in a population of 400 volunteers with mild to moderate blood pressure elevation (systolic blood pressure between 130 mmHg and 159 mmHg and diastolic pressure <100 mmHg). It will include two groups: a TOTUM•854 group with a dose of 3.7 g/day and a placebo group. Its main objective will be to reduce systolic blood pressure in the TOTUM•854 group after 3 months of supplementation versus the placebo group. 24-hour ambulatory blood pressure measurements will also be taken as a secondary study endpoint. The end of recruitment is expected at the first semester of 2023. A second INSIGHT 2 international, multicenter, randomized, placebo-controlled study will be conducted on 400 additional subjects with the same inclusion criteria. It will include two groups: a TOTUM•854 group with a dose of 2.6 g/day and a placebo group. Its main objective will be to reduce systolic blood pressure in the TOTUM•854 group after 3 months of supplementation versus the placebo group. It will thus assess the effect of a reduced dose of TOTUM•854 (2.6 g/day) on blood pressure. The end of recruitment is expected at the first semester of 2023. The clinical study of the bioavailability and mode of action of TOTUM•854, to characterize its metabolites and identify their effects on human cell lines, will be conducted in France on 10 volunteers. The results are expected at the end of 2022. Murielle CAZAUBIEL, Member of the Board of Directors and Director of Medical, Regulatory and Industrial Affairs at
Valbiotis
, said: “TOTUM•854’s clinical development plan is very ambitious, but meets the health challenges of preventing
arterial hypertension
, which the World Health Organization considers to be the world’s most prevalent
chronic disease
. It is a very important risk factor for
cardiovascular disease
. TOTUM•854 could quickly become an extremely interesting non-drug alternative for people at risk, whether or not they are already taking treatment. This innovative active substance, which contains six plant extracts, is designed to act on blood pressure regulation mechanisms. It would ultimately be produced in various dry forms, including as capsules.” Sébastien BESSY, Member of the
Board
of Directors and Chief Operating Marketing and Business Officer at
Valbiotis
, comments: “TOTUM•854 will open the door to a major market worth over €1.15 billion1 in the United States and in the five main European countries (Germany, Spain, France, Italy and the United Kingdom), where no fewer than 124 million people suffer from mild to moderate
arterial hypertension
. This clinical development plan will leverage the potential of TOTUM•854 in preventing
arterial hypertension
, with the aim of bringing it to market as soon as the studies ends. In addition, we have registered TOTUM•854 in over 60 countries, including our key territories such as the United States, Europe, Mexico, China, Japan and already obtained in some of these territories.” Valbiotis presented its preclinical data on the active substance TOTUM•854 at the annual meeting of the European Society of
Hypertension
and of the International Society of
Hypertension
in April 2021. The in vivo results obtained from two predictive models of
hypertension
in humans showed that TOTUM•854 effectively prevented
arterial hypertension
. This proof-of-concept was obtained in partnership with the Cardiovascular Pharm-Ecology
Lab
(LaPEC) of the
University of Avignon
and at the Valbiotis R&D platform. The research presented at the meeting was conducted on a model of
L-NAME-induced hypertension
(an NO synthase inhibitor). In this classic model of
hypertension
, predictive of human physiology, TOTUM•854 prevented the onset of
arterial hypertension
compared with the control group. Additional data, obtained from a polygenic SHR (spontaneously hypertensive rat) model of
hypertension
, also showed a positive effect of TOTUM•854 that delays the development of
hypertension
. A significant acute effect was also observed following a single dose of TOTUM•854 on the same SHR model. About
Valbiotis
Valbiotis
is a
Research & Development company
committed to scientific innovation for preventing and combating
metabolic diseases
in response to unmet medical needs.
Valbiotis
has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of health nutrition products designed to reduce the risk of major
metabolic diseases
, relying on a multi-target strategy enabled by the use of plant-based terrestrial and marine resources. Its products are intended to be licensed to players in the health sector. Created at the beginning of 2014 in La Rochelle, the Company has forged numerous partnerships with leading academic centers. The Company has established three sites in France – Périgny, La Rochelle (17) and Riom (63) – and a subsidiary in Quebec City (Canada).
Valbiotis
is a member of the "BPI Excellence" network and has been recognized as an "
Innovative Company
" by the BPI label.
Valbiotis
has also been awarded "
Young Innovative Company
" status and has received major financial support from the European Union for its research programs via the European
Regional Development
Fund (ERDF).
Valbiotis
is a PEA-SME eligible company. For more information about
Valbiotis
, please visit: Name:
Valbiotis
ISIN code: FR0013254851 Ticker symbol: ALVAL EnterNext© PEA-PME 150 This press release contains forward-looking statements about
Valbiotis
’ objectives.
Valbiotis
considers that these projections are based on rational hypotheses and the information available to
Valbiotis
at the present time. However, in no way does this constitute a guarantee of future performance, and these projections may be affected by changes in economic conditions and financial markets, as well as certain risks and uncertainties, including those described in the
Valbiotis
Universal Registration Document approved by the French Financial Markets Regulator (AMF) on July 27, 2021 (application number R 21-039). This document is available on the Company’s website ( ). This press release and the information it contains do not constitute an offer to sell or subscribe, or a solicitation to purchase or subscribe to
Valbiotis
’ shares or financial securities in any country. 1Source:
AEC Partners
pre-AHT preliminary market estimate 2020 data View source version on businesswire.com: Contacts Corporate communication /
Valbiotis
Carole Rocher / Marc Delaunay +33 5 46 28 62 58 media@valbiotis.com Financial communication / Actifin Stéphane Ruiz +33 1 56 88 11 14 sruiz@actifin.fr Source:
Valbiotis
View this news release online at:
机构
l'Université d'Avignon
再鼎医药(上海)有限公司
C h Fernandes Tecnologia
[+6]
适应症
心血管疾病
高血压
慢性病
[+1]
靶点
-
药物
-
标准版
¥
16800
元/账号/年
新药情报库 | 省钱又好用!
立即使用
来和芽仔聊天吧
热门报告
特应性皮炎深度解析:药物开发、专利分析与风险评估
智慧芽生物医药
2024年7月全球首批及特殊审评药物报告
智慧芽生物医药
GPRC5D靶点专利调研报告
智慧芽生物医药
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
开始免费试用
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。
试用数据服务